CATL Shares Fall as Hungary Plant Faces Safety Halt 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Add as a preferred source on Google
Pompano Beach, FL, March 13, 2018 -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a focus in Pharmaceuticals and Regenerative Medicine, announced today the addition of Dr. Felix Amon, who will consult BSEM with Pharmaceutical Business Development.
Dr. Felix Amon has two decades of product management, medical innovation and business development experience in healthcare and related industries, including three years as a Product Manager for Eli Lilly, 2 years as as the Austria Marketing and Sales Director for Merck (MSD) Europe, followed by leading the Ophthalmics business in Merck’s ww Headquarter in Whitehouse Station, New Jersey where he managed Planning and Project Management for a $650 million business operating in 104 countries. He also completed the development of an European Sales and Marketing Campaign for BIOGEN’s Avonex and implemented the launch of Avonex in Germany, Austria and Switzerland. Dr. Amon has an MBA (1987) from Emory University in Atlanta, Georgia, and a PhD in Law (1985) from Linz – Johannes Keppler University in Austria.
BSEM’s, COO, Andrew Van Vurst stated, “The addition of Dr. Amon to our team is imperative in the Companies’ mission to discover, develop and market novel Pharmaceutical and Regenerative Medicine products. We look forward to leveraging his experience in the development of sales and marketing strategies for BioStem Technologies pharmaceutical portfolio.”
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risk factors, as discussed in reports filed by the Company with OTC Markets.
BioStem Technologies, Inc. Phone: 954-380-8342 Website: http://www.biostemtech.com Email: [email protected] Twitter: @Biostemtech Facebook: BioStem Technologies Investor Relations: Andrew Van Vurst [email protected] (954) 380-8342
